Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability 3-09-2024, 19:00
SmarTone Selects Covalensedigital for BSS Transformation with Csmart and Oracle Cloud Native Solutions 13-06-2024, 13:13